These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25393958)

  • 1. Function-based mutation-resistant synthetic signaling device activated by HIV-1 proteolysis.
    Majerle A; Gaber R; Benčina M; Jerala R
    ACS Synth Biol; 2015 Jun; 4(6):667-72. PubMed ID: 25393958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.
    Sices HJ; Leusink MD; Pacheco A; Kristie TM
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1249-55. PubMed ID: 11559424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.
    Dauber DS; Ziermann R; Parkin N; Maly DJ; Mahrus S; Harris JL; Ellman JA; Petropoulos C; Craik CS
    J Virol; 2002 Feb; 76(3):1359-68. PubMed ID: 11773410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.
    Braz AS; Tufanetto P; Perahia D; Scott LP
    Proteins; 2012 Dec; 80(12):2680-91. PubMed ID: 22821809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
    Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
    Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
    Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
    Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
    J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
    Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
    Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A heterologous substrate assay for the HIV-1 protease engineered in Escherichia coli.
    Stebbins J; Deckman IC; Richardson SB; Debouck C
    Anal Biochem; 1996 Nov; 242(1):90-4. PubMed ID: 8923970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure.
    Boeri E; Gianotti N; Canducci F; Hasson H; Giudici B; Castagna A; Lazzarin A; Clementi M
    AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1151-3. PubMed ID: 14714567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
    Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
    J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
    Lam E; Parkin NT
    Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
    [No Abstract]   [Full Text] [Related]  

  • 19. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.
    Cherry E; Morin N; Wainberg MA
    AIDS; 1998 Jun; 12(9):967-75. PubMed ID: 9662192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.